Type-I AIE photosensitizer triggered cascade catalysis system for tumor targeted therapy and postoperative recurrence suppression

Huang, Chunyu1,2,8; Zhang, Tianfu5,6; Li, Yang1,2; Lyu, Meng7; Suo, Meng7; Xia, Ligang1,2; Liu, Lingrong4; Tang, Benzhong3; Zhang, Qiqing1,2

2022-10-15

10.1016/j.cej.2022.136381

CHEMICAL ENGINEERING JOURNAL   影响因子和分区

1385-8947

1873-3212

Aggregation-induced emission luminogens (AIEgens) based photodynamic therapy (PDT) has been emerging as a promising anti-cancer strategy. However, the short life span of many active oxygen species (ROS) reduces its therapeutic effect. Enhancing and maintaining the production of ROS in tumor cells remains a challenge. In this work, we constructed a tumor exosome bionic SAZs /AIEgens cascade catalysis system (CCS) for enhanced center dot OH generation and facilitating efficient tumor penetration. First, we prepared a Cu single atom nanozyme (Cu SAZs) with peroxidase activity, followed by coating with AIEgens absorbed tumor derived exosomes (TDE) to construct the CCS. The CCS system can penetrate tumor tissue after intravenous injection, and then TBP-2 generates center dot OH and hydrogen peroxide (H2O2) through type-1 PDT. Next, the H2O2 interacts with the Cu SAZs, resulting in the production of center dot OH in the tumor. The SGC 7901 tumor model experimental results revealed that the CCS systems significantly suppress tumor growth and efficiently cause tumor immunogenic cell death (ICD). CCS satisfies the requirement for enhanced and continuous generation of center dot OH, as well as compensates for the deficiency of H2O2 in SAZ-catalyzed therapy. More importantly, we found that CCS can effectively inhibit tumor recurrence in the CT26 recurrent mouse tumor model after surgery and has good clinical application potential.

Aggregation-induced emission Single-atom nanozyme Type-I photodynamic therapy Continuous hydroxyl radical generation Postoperative recurrence suppression

SCI

英语

第一 ; 通讯

Guangdong basic and Applied Basic Research Fund Regional Joint Fund Project (key project)[2020B1515120091] ; Shenzhen Basic Research Special (Natural Science Fund) basic research surface project[JCYJ20210324113006017] ; National Key Basic Researchand Development Projects["2017YFC1103601","2017YFC1104102"]

Engineering

Engineering, Environmental ; Engineering, Chemical

WOS:000833418900001

ELSEVIER SCIENCE SA

ENGINEERING

Web of Science

1.Southern Univ Sci & Technol, Jinan Univ, Affiliated Hosp 1,Inst Biomed Engn, Shenzhen Peoples Hosp,Clin Med Coll 2, Shenzhen 518020, Guangdong, Peoples R China
2.Southern Univ Sci & Technol, Jinan Univ, Affiliated Hosp 1,Dept Gastrointestinal Surg, Shenzhen Peoples Hosp,Clin Med Coll 2, Shenzhen 518020, Guangdong, Peoples R China
3.Chinese Univ Hong Kong, Sch Sci & Engn, Shenzhen Inst Mol Aggregate Sci & Engn, 2001 Longxiang Blvd, Shenzhen 518172, Guangdong, Peoples R China
4.Chinese Acad Med Sci & Peking Union Med Coll, Inst Biomed Engn, Tianjin 300192, Peoples R China
5.Hong Kong Univ Sci & Technol, Chinese Natl Engn Res Ctr Tissue Restorat, Dept Chem, Hong Kong Branch,Kowloon, Clear Water Bay, Hong Kong 999077, Peoples R China
6.Hong Kong Univ Sci & Technol, Inst Adv Study, Kowloon, Clear Water Bay, Hong Kong 999077, Peoples R China
7.Wuhan Univ, Zhongnan Hosp, Hubei Canc Clin Study Ctr, Hubei Key Lab Tumor Biol Behav,Dept Radiat & Med, Wuhan 430071, Peoples R China
8.Wuhan Univ, Sch Phys & Technol, Minist Educ, Key Lab Artificial Micro & Nanostruct, Wuhan 430072, Peoples R China

Huang, Chunyu,Zhang, Tianfu,Li, Yang,et al. Type-I AIE photosensitizer triggered cascade catalysis system for tumor targeted therapy and postoperative recurrence suppression[J]. CHEMICAL ENGINEERING JOURNAL,2022,446.

Huang, Chunyu.,Zhang, Tianfu.,Li, Yang.,Lyu, Meng.,Suo, Meng.,...&Zhang, Qiqing.(2022).Type-I AIE photosensitizer triggered cascade catalysis system for tumor targeted therapy and postoperative recurrence suppression.CHEMICAL ENGINEERING JOURNAL,446.

Huang, Chunyu,et al."Type-I AIE photosensitizer triggered cascade catalysis system for tumor targeted therapy and postoperative recurrence suppression".CHEMICAL ENGINEERING JOURNAL 446(2022).